Rani Therapeutics Holdings reported second quarter 2026 financial results, posting a net loss of $8.4 million compared to $11.2 million in the prior year period. Cash and marketable securities totaled $53.4 million as of June 30, 2026, up from $43.4 million at March 31, 2026. The company completed a $20 million registered direct offering in May 2026 to strengthen its cash position. Clinically, Rani dosed the first participants in the Phase 1a expansion cohort of RT-114 and announced positive initial data showing oral bioavailability exceeding matched subcutaneous dosing by over 150%. The company also entered a research collaboration with PegBio for obesity pipeline candidates and appointed Nicholas Maestas as CFO and Michelle Gilson to its Board. Rani Therapeutics is a clinical-stage biotechnology company focused on developing the RaniPill oral delivery platform for biologics.

Rani Therapeutics Holdings, Inc. appointed Michelle Gilson to its Board of Directors effective August 1, 2026. Ms. Gilson also assumed the role of Chair of the Audit Committee. She previously served as Chief Financial Officer of Arcellx, Inc., until its acquisition by Gilead Sciences in April 2026, and has extensive experience in biotechnology equity research and investment banking at firms including Canaccord Genuity, Jefferies, Nomura, Oppenheimer, and Goldman Sachs. The company entered into a standard indemnification agreement with Ms. Gilson. Rani Therapeutics Holdings, Inc. operates in the pharmaceutical industry, developing therapies for rare diseases.

Rani Therapeutics Holdings, Inc. announced the appointment of Nicholas M. Maestas as Chief Financial Officer, effective June 29, 2026, succeeding Svai Sanford. Mr. Maestas's compensation package includes a $500,000 annual base salary, a 75% target bonus, and a grant of 2,000,000 Class A common stock options under the 026 Equity Inducement Plan. The company's Board of Directors also approved a 2026 Equity Inducement Plan, reserving 5,500,000 shares for inducement awards. Rani Therapeutics Holdings, Inc. is a biotechnology company focused on developing oral delivery technologies for oral drug delivery systems.